Literature DB >> 33246974

Interim PET in Diffuse Large B-Cell Lymphoma.

Lars Kurch1, Andreas Hüttmann2, Thomas W Georgi3, Jan Rekowski4, Osama Sabri3, Christine Schmitz2, Regine Kluge3, Ulrich Dührsen2, Dirk Hasenclever5.   

Abstract

In diffuse large B-cell lymphoma, early assessment of treatment response by 18F-FDG PET may trigger treatment modification. Reliable identification of good and poor responders is important. We compared 3 competing methods of interim PET evaluation.
Methods: Images from 449 patients participating in the "PET-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" trial were reanalyzed by applying the visual Deauville score and the SUV-based qPET (q = quantitative) and ΔSUVmax scales to interim PET scans performed after 2 cycles of chemotherapy. qPET relates residual lymphoma 18F-FDG uptake to physiologic liver uptake, converting the ordinal Deauville scale into a continuous scale and permitting a direct comparison with the continuous ΔSUVmax scale, which is based on SUVmax changes between baseline and interim scans. Positive and negative predictive values were calculated for progression-free survival.
Results: When established thresholds were used to distinguish between good and poor responders (visual Deauville score 1-3 vs. 4-5; ΔSUVmax > 66% vs. ≤ 66%), the positive predictive value was significantly lower with Deauville than ΔSUVmax (38.4% vs. 56.6%; P = 0.03). qPET and ΔSUVmax were strongly correlated on the log scale (Pearson r = 0.75). When plotted along corresponding percentiles, the positive predictive value curves for qPET and ΔSUVmax were superimposable, with low values up to the 85th percentile and a steep rise thereafter. The recommended threshold of 66% SUVmax reduction for the identification of poor responders was equivalent to qPET = 2.26, corresponding to score 5 on the visual Deauville scale. The negative predictive value curves were also superimposable but remained flat between 80% and 70%.
Conclusion: Continuous scales are better suited for interim PET-based outcome prediction than the ordinal Deauville scale. qPET and ΔSUVmax essentially carry the same information. The proportion of poor-risk patients identified is less than 15%.
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  Deauville scale; PET; PETAL trial; diffuse large B-cell lymphoma; interim evaluation; qPET; ΔSUVmax

Mesh:

Substances:

Year:  2020        PMID: 33246974     DOI: 10.2967/jnumed.120.255034

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  8 in total

1.  Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients.

Authors:  J J Eertink; C N Burggraaff; M W Heymans; U Dührsen; A Hüttmann; C Schmitz; S Müller; P J Lugtenburg; S F Barrington; N G Mikhaeel; R Carr; S Czibor; T Györke; L Ceriani; E Zucca; M Hutchings; L Kostakoglu; A Loft; S Fanti; S E Wiegers; S Pieplenbosch; R Boellaard; O S Hoekstra; J M Zijlstra; H C W de Vet
Journal:  Blood Adv       Date:  2021-05-11

2.  [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies.

Authors:  Dan Cohen; Efrat Luttwak; Ofrat Beyar-Katz; Shir Hazut Krauthammer; Yael Bar-On; Odelia Amit; Ronit Gold; Chava Perry; Irit Avivi; Ron Ram; Einat Even-Sapir
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-09-04       Impact factor: 9.236

3.  Reproducibility of [18F]FDG PET/CT liver SUV as reference or normalisation factor.

Authors:  Gerben J C Zwezerijnen; Jakoba J Eertink; Maria C Ferrández; Sanne E Wiegers; Coreline N Burggraaff; Pieternella J Lugtenburg; Martijn W Heymans; Henrica C W de Vet; Josée M Zijlstra; Ronald Boellaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-09-27       Impact factor: 10.057

4.  Risk Assessment in Diffuse Large B-Cell Lymphoma by Combining Baseline Metabolic Tumor Volume and Peking Criteria When Evaluating Series 18F-Fluorodeoxyglucose Positron Emission Tomography Scans.

Authors:  Tingting Yuan; Yuewei Zhang; Xuetao Chen; Maomao Wei; Hua Zhu; Yuqin Song; Zhi Yang; Jun Zhu; Xuejuan Wang
Journal:  Front Oncol       Date:  2022-04-21       Impact factor: 5.738

5.  Risk Stratification for Diffuse Large B-Cell Lymphoma by Integrating Interim Evaluation and International Prognostic Index: A Multicenter Retrospective Study.

Authors:  Xue Shi; Xiaoqian Liu; Xiaomei Li; Yahan Li; Dongyue Lu; Xue Sun; Ying Li; Shunfeng Hu; Yuanfeng Zhang; Xiangxiang Zhou; Xin Wang; Haiping Chen; Xiaosheng Fang
Journal:  Front Oncol       Date:  2021-12-16       Impact factor: 6.244

6.  Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial.

Authors:  Jia Jin; Dongmei Ji; Zuguang Xia; Kai Xue; Qunling Zhang; Yizhen Liu; Junning Cao; Xiaonan Hong; Juan J Gu; Ye Guo; Fangfang Lv
Journal:  BMC Cancer       Date:  2022-04-13       Impact factor: 4.430

Review 7.  [Lymphoma in children and adolescents].

Authors:  Ina Sorge; Thomas Walter Georgi; Franz Wolfgang Hirsch
Journal:  Radiologe       Date:  2021-06-23       Impact factor: 0.635

8.  Vital Hepatic Lymphoma Residuum or Excessive Immune Response? Challenging Treatment Decisions in a Patient With Systemic Lupus Erythematosus and Liver-Dominant Diffuse Large B-Cell Lymphoma: Case Report.

Authors:  Lars Kurch; Thomas W Georgi; Astrid Monecke; Daniel Seehofer; Gudrun Borte; Osama Sabri; Regine Kluge; Simone Heyn; Matthias Pierer; Uwe Platzbecker; Sabine Kayser
Journal:  Front Oncol       Date:  2022-01-18       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.